GO:0042694 muscle cell fate specification: Smooth Muscle Phenotypic Switching, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042694 (muscle cell fate specification) is the biological process by which a cell becomes capable of differentiating autonomously into a muscle cell in a neutral environment, and this fate can still be reversed.
• In adult vasculature, smooth muscle cells (SMCs) are not terminally fixed; single-cell genomics has identified intermediate cell states during SMC phenotypic switching in atherosclerosis.
• SMC reprogramming toward macrophage-like or fibroblast-like states contributes to aortic aneurysm, atherosclerosis and fibrosis.
• Spatiotemporal transcription factor expression, such as ATF3, determines vascular SMC fate in abdominal aortic aneurysm.
• Macrophage subsets and injury-responsive signaling orchestrate monocyte recruitment and fate specification after myocardial injury.
• CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of genes controlling muscle cell fate specification.
Description
GO:0042694, muscle cell fate specification, describes the developmental process in which a cell becomes capable of differentiating autonomously into a muscle cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed. This term is central to understanding how muscle lineages are established and how they can be redirected in disease. In the vasculature, smooth muscle cells retain remarkable plasticity, and single-cell genomics has revealed a novel cell state during smooth muscle cell phenotypic switching in mouse and human atherosclerosis. Because specification is reversible, it represents a therapeutic window in which cell fate can be stabilized or reprogrammed.
muscle cell fate specification At A Glance
| GO ID | GO:0042694 |
|---|---|
| GO term | muscle cell fate specification |
| Ontology | biological_process |
| Synonym | none |
| Major function | Acquisition of autonomous muscle differentiation potential in a neutral environment, with reversible fate |
| Reversibility | Upon specification, the cell fate can be reversed |
| Related cell types | Smooth muscle cells, cardiac muscle cells, skeletal muscle cells |
| Disease relevance | Atherosclerosis, aortic aneurysm, myocardial injury, fibrosis |
| Research methods | Single-cell genomics, lineage tracing, CRISPR editing, transcriptomics |
What Is GO:0042694?
Muscle cell fate specification (GO:0042694) is the process in which a cell becomes capable of differentiating autonomously into a muscle cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed. In practice, this means the cell has acquired a muscle-directed potential but is not yet committed, so external or intrinsic signals can still shift it toward another fate. This reversibility distinguishes specification from later determination and differentiation steps.
Why Is muscle cell fate specification Important in Cell Biology?
Muscle cell fate specification is important because it defines the point at which a cell can autonomously become muscle, yet remains reversible, making it a key target for understanding and manipulating tissue repair and disease. In atherosclerosis, single-cell genomics has revealed a novel cell state during smooth muscle cell phenotypic switching, highlighting how fate specification contributes to plaque progression. In aortic aneurysms, smooth muscle cell reprogramming is a central mechanism of disease. Thus, the term connects developmental biology to major cardiovascular pathologies.
• Defines the reversible step before terminal muscle differentiation.
• Explains smooth muscle cell phenotypic switching in atherosclerosis.
• Underlies smooth muscle cell reprogramming in aortic aneurysms.
• Links macrophage signaling to monocyte recruitment and fate specification after myocardial injury.
• Involves spatiotemporal transcription factor control, such as ATF3 in abdominal aortic aneurysm.
• Contributes to fibrosis through injury-responsive fibroblast activation.
• Relevant to macrophage-like smooth muscle cells in advanced atherosclerotic plaque.
• Provides targets for CRISPR-based cell fate manipulation.
• Supports regenerative strategies for cardiovascular disease.
• Connects extracellular matrix remodeling to cell fate decisions.
What Happens During muscle cell fate specification?
Acquisition of autonomous muscle potential
In simple terms: A cell gains the ability to become muscle on its own.
During specification, a cell becomes capable of differentiating autonomously into a muscle cell in an environment that is neutral with respect to the developmental pathway. This step is marked by the activation of muscle-associated transcriptional programs while the cell remains responsive to external cues. Single-cell genomics has captured such transitional states during smooth muscle cell phenotypic switching.
Reversible intermediate cell states
In simple terms: The cell is not locked in yet and can still change direction.
Upon specification, the cell fate can be reversed. This reversibility is evident in vascular smooth muscle cells, which can shift toward macrophage-like or fibroblast-like states in disease. The existence of intermediate states during phenotypic switching supports the idea that specification is a dynamic, modifiable process.
Transcriptional control by spatiotemporal factors
In simple terms: Timing and location of transcription factors decide the cell's direction.
Spatiotemporal expression of transcription factors such as ATF3 determines vascular smooth muscle cell fate in abdominal aortic aneurysm. This indicates that specification is not a single event but a regulated trajectory influenced by when and where key regulators are expressed.
Signaling from immune and matrix microenvironments
In simple terms: Immune cells and the surrounding matrix send signals that guide fate.
Tissue-resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. In addition, ADAMTS12 promotes fibrosis by restructuring the extracellular matrix to enable activation of injury-responsive fibroblasts. These findings show that specification is modulated by both immune signaling and matrix remodeling.
Metabolic and stress-related modulation
In simple terms: Cellular stress and metabolism can influence whether a cell becomes muscle.
OGT deficiency in vascular smooth muscle orchestrates foam cell formation and PANoptosis during atherosclerotic progression. Enhancer-associated lncRNA-ITGA2 promotes vascular remodeling through ITGA2. Such metabolic and stress-related pathways can intersect with fate specification programs in vascular disease.
Key Genes Involved in GO:0042694 muscle cell fate specification
The following genes and proteins have been implicated in muscle cell fate specification and related vascular smooth muscle cell state changes in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ATF3 | Spatiotemporal transcription factor determining VSMC fate | Abdominal aortic aneurysm |
| CCR2 | Macrophage subset marker orchestrating monocyte recruitment and fate specification | Myocardial injury |
| ADAMTS12 | Extracellular matrix remodeling enabling fibroblast activation | Fibrosis |
| ITGA2 | Enhancer-associated lncRNA target promoting vascular remodeling | Vascular remodeling |
| OGT | O-GlcNAc transferase; deficiency drives foam cell formation and PANoptosis | Atherosclerosis |
| MYH11 | Smooth muscle contractile marker | SMC phenotypic switching |
| ACTA2 | Smooth muscle actin; contractile SMC marker | SMC phenotypic switching |
| LGALS3 | Macrophage-like SMC marker | Advanced atherosclerotic plaque |
| CD68 | Macrophage marker used to identify macrophage-like SMCs | Atherosclerosis |
| KLF4 | Transcription factor associated with SMC phenotypic modulation | SMC reprogramming |
| MYOCD | Master regulator of smooth muscle differentiation | SMC fate |
| SRF | Serum response factor cooperating with MYOCD | SMC fate |
| TGFB1 | Cytokine influencing SMC phenotype | Aortic aneurysm |
| PDGFB | Growth factor promoting SMC phenotypic switching | Atherosclerosis |
| IL1B | Inflammatory cytokine linked to SMC reprogramming | Aortic aneurysm |
| TNF | Inflammatory cytokine affecting SMC state | Atherosclerosis |
| COL1A1 | Extracellular matrix component in fibrosis | Fibrosis |
How Is muscle cell fate specification Regulated?
Muscle cell fate specification is regulated by a combination of transcription factors, immune signaling and matrix remodeling. Spatiotemporal ATF3 expression determines vascular smooth muscle cell fate in abdominal aortic aneurysm. Tissue-resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. ADAMTS12 promotes fibrosis by restructuring the extracellular matrix to enable activation of injury-responsive fibroblasts. In addition, OGT deficiency in vascular smooth muscle orchestrates foam cell formation and PANoptosis during atherosclerotic progression, and enhancer-associated lncRNA-ITGA2 promotes vascular remodeling through ITGA2. These layers of regulation collectively influence whether a cell acquires and maintains a muscle fate or switches to an alternative state.
muscle cell fate specification and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ATF3 | Abdominal aortic aneurysm | VSMC-specific knockout and overexpression |
| CCR2 | Myocardial injury and monocyte fate specification | CCR2 knockout and macrophage depletion |
| ADAMTS12 | Fibrosis and matrix remodeling | ADAMTS12 knockout fibroblasts |
| ITGA2 | Vascular remodeling | ITGA2 enhancer knockout and overexpression |
| OGT | Atherosclerosis and PANoptosis | VSMC-specific OGT knockout |
Atherosclerosis and smooth muscle cell phenotypic switching
Single-cell genomics has revealed a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human. Re-analysis of single-cell transcriptomics further reveals a critical role of macrophage-like smooth muscle cells in advanced atherosclerotic plaque. OGT deficiency in vascular smooth muscle orchestrates foam cell formation and PANoptosis during atherosclerotic progression. These studies link muscle cell fate specification to plaque progression and identify candidate targets.
Aortic aneurysm and SMC reprogramming
Smooth muscle cell reprogramming is a key mechanism in aortic aneurysms. Spatiotemporal ATF3 expression determines VSMC fate in abdominal aortic aneurysm. Enhancer-associated lncRNA-ITGA2 promotes vascular remodeling through ITGA2. Together, these findings show that disruption of normal SMC fate specification contributes to aneurysm formation and vascular remodeling.
Myocardial injury and immune-driven fate specification
Tissue-resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. This indicates that immune cell subsets can direct the fate of recruited cells after cardiac damage, connecting muscle cell fate specification to repair and remodeling.
Fibrosis and matrix remodeling
ADAMTS12 promotes fibrosis by restructuring the extracellular matrix to enable activation of injury-responsive fibroblasts. Because matrix cues influence cell fate, this pathway may intersect with muscle cell fate specification in fibrotic tissues.
From muscle cell fate specification-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is ATF3 required for VSMC fate in aneurysm? | VSMC-specific ATF3 knockout mouse |
| Does CCR2 mark macrophages that direct fate specification? | CCR2 knockout and fate-mapping models |
| Does ADAMTS12 remodel matrix to enable fibroblast activation? | ADAMTS12 knockout and overexpression |
| Does ITGA2 enhancer regulate vascular remodeling? | Enhancer knockout and knock-in reporter |
| Does OGT loss drive foam cell formation and PANoptosis? | VSMC-specific OGT knockout |
| Can SMC phenotypic switching be reversed? | Lineage tracing and single-cell genomics |
How to Study the muscle cell fate specification Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Single-cell RNA-seq | Cell states and transitions | SMC phenotypic switching |
| Lineage tracing | Cell origin and fate | SMC reprogramming |
| Spatiotemporal expression analysis | Timing and location of regulators | ATF3 in aneurysm |
| CRISPR knockout | Loss-of-function causality | OGT in atherosclerosis |
| Enhancer reporter assays | Regulatory element activity | ITGA2 enhancer |
| Macrophage depletion | Immune contribution to fate | CCR2+ macrophages |
| Matrix remodeling assays | Extracellular matrix effects | ADAMTS12 in fibrosis |
Single-cell genomics and transcriptomics
Single-cell genomics has been used to reveal a novel cell state during smooth muscle cell phenotypic switching in mouse and human atherosclerosis. Re-analysis of single-cell transcriptomics identified macrophage-like smooth muscle cells in advanced atherosclerotic plaque. These approaches resolve intermediate states that define muscle cell fate specification.
Lineage tracing and fate mapping
Lineage tracing is essential to determine whether a cell has acquired a muscle fate or switched to another state. Studies of smooth muscle cell reprogramming in aortic aneurysms and macrophage fate specification after myocardial injury have used such approaches to track cell origins and transitions.
Spatiotemporal expression analysis
Spatiotemporal ATF3 expression determines VSMC fate in abdominal aortic aneurysm, illustrating the value of time-resolved and location-resolved expression analysis. Enhancer-associated lncRNA-ITGA2 studies further show how regulatory elements can be mapped to vascular remodeling.
CRISPR functional screens and validation
CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of candidate genes identified by genomics. For example, VSMC-specific OGT knockout was used to link OGT deficiency to foam cell formation and PANoptosis in atherosclerosis. Such functional validation is critical to move from correlation to causation in muscle cell fate specification research.
How CRISPR Can Be Used to Study GO:0042694 muscle cell fate specification
Knockout
CRISPR knockout is used to test whether a candidate gene is required for muscle cell fate specification. For example, VSMC-specific OGT knockout was used to show that OGT deficiency orchestrates foam cell formation and PANoptosis during atherosclerotic progression. Knockout of transcription factors such as ATF3 can test their role in determining VSMC fate in abdominal aortic aneurysm.
Point Mutation
Point-mutation models allow precise testing of phosphorylation sites, DNA-binding residues or catalytic residues in genes controlling muscle cell fate specification. Such edits can reveal whether specific residues in regulators like ATF3 or OGT are required for fate decisions, based on pathways implicated in aneurysm and atherosclerosis.
Knock-in
Knock-in of reporters or tags enables visualization and tracking of cells undergoing muscle cell fate specification. Enhancer-associated lncRNA-ITGA2 studies illustrate how regulatory elements can be interrogated with knock-in approaches to understand vascular remodeling. Tagged knock-in of SMC markers can help resolve intermediate states during phenotypic switching.
Overexpression
Overexpression models test sufficiency of a gene to drive or block muscle cell fate specification. Overexpression of matrix-remodeling factors such as ADAMTS12 can promote fibrosis-associated fibroblast activation, while overexpression of ITGA2-related elements can promote vascular remodeling. These models complement knockout studies to establish causality.
How EDITGENE Supports muscle cell fate specification Research
Researchers studying muscle cell fate specification-related genes often need to determine whether a candidate gene is causally involved in fate decisions or is merely correlated with a cell state. EDITGENE provides CRISPR-based cell models and screening services to test causality in relevant muscle and vascular cell backgrounds.
Contact EDITGENE today to design your custom CRISPR model for muscle cell fate specification research.
Frequently Asked Questions About muscle cell fate specification
What is muscle cell fate specification GO:0042694?
It is the biological process in which a cell becomes capable of differentiating autonomously into a muscle cell in a neutral environment, and the fate can be reversed.
What genes are involved in muscle cell fate specification?
Genes implicated in related vascular SMC fate changes include ATF3, CCR2, ADAMTS12, ITGA2 and OGT.
Why is muscle cell fate specification important in atherosclerosis?
Single-cell genomics revealed a novel cell state during smooth muscle cell phenotypic switching in atherosclerosis, linking fate specification to plaque progression.
How is muscle cell fate specification studied?
It is studied with single-cell genomics, lineage tracing, spatiotemporal expression analysis and CRISPR functional models.
What is the role of ATF3 in muscle cell fate specification?
Spatiotemporal ATF3 expression determines VSMC fate in abdominal aortic aneurysm.
How do macrophages influence muscle cell fate specification?
Tissue-resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury.
Can muscle cell fate specification be reversed?
Yes, upon specification the cell fate can be reversed, as indicated by the GO definition and observed SMC phenotypic switching.
What diseases are linked to muscle cell fate specification?
Atherosclerosis, aortic aneurysm, myocardial injury and fibrosis have been linked to SMC fate changes.
What CRISPR models are used for muscle cell fate specification?
Knockout, point-mutation, knock-in and overexpression models are used to test causality of candidate genes.
What is the role of OGT in vascular smooth muscle fate?
OGT deficiency in vascular smooth muscle orchestrates foam cell formation and PANoptosis during atherosclerotic progression.
Conclusion
GO:0042694 muscle cell fate specification defines a reversible step in which cells acquire the potential to become muscle. In cardiovascular biology, this process is central to smooth muscle cell phenotypic switching, aneurysm, atherosclerosis and injury repair. CRISPR-based models provide a direct way to test the causal roles of genes such as ATF3, OGT and ITGA2 in these fate decisions.
References
- 1. Pan H et al.. 2020. Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human.. Circulation 142(21):2060-2075 PMID: 32962412
- 2. Chen PY et al.. 2020. Smooth Muscle Cell Reprogramming in Aortic Aneurysms.. Cell Stem Cell 26(4):542-557.e11 PMID: 32243809
- 3. Bajpai G et al.. 2019. Tissue Resident CCR2- and CCR2+ Cardiac Macrophages Differentially Orchestrate Monocyte Recruitment and Fate Specification Following Myocardial Injury.. Circ Res 124(2):263-278 PMID: 30582448
- 4. Wen Y et al.. 2024. Spatiotemporal ATF3 Expression Determines VSMC Fate in Abdominal Aortic Aneurysm.. Circ Res 134(11):1495-1511 PMID: 38686580
- 5. Hoeft K et al.. 2024. ADAMTS12 promotes fibrosis by restructuring extracellular matrix to enable activation of injury-responsive fibroblasts.. J Clin Invest 134(18) PMID: 39286973
- 6. Gong X et al.. 2024. Re-analysis of single-cell transcriptomics reveals a critical role of macrophage-like smooth muscle cells in advanced atherosclerotic plaque.. Theranostics 14(4):1450-1463 PMID: 38389849
- 7. Guo X et al.. 2025. Enhancer-Associated LncRNA-ITGA2 Promotes Vascular Remodeling Through ITGA2.. Circ Res 136(12):1610-1628 PMID: 40321134
- 8. Liu B et al.. 2026. OGT deficiency in vascular smooth muscle orchestrates foam cell formation and PANoptosis during atherosclerotic progression.. Atherosclerosis 412:120604 PMID: 41297071
